Compare Crispr Therapeutics AG (CRSP) vs Oracle Corporation (ORCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Oracle Corporation — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Oracle Corporation trades at $141.53 (market cap $411.34B). The key difference: Oracle Corporation is far larger — about 84.3× Crispr Therapeutics AG's market cap, and Oracle Corporation pays a 1.47% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Oracle Corporation for 72 Days on average.
| CRSP | ORCL | |
|---|---|---|
Market Cap | $4.88B | $411.34B |
Volume | 2,861,747 | 41,276,815 |
Sector | Health | Technology |
52-Week High | $74.92 | $313.00 |
52-Week Low | $44.34 | $114.99 |
Typical Hold Time | 77 Days | 72 Days |
Enterprise Value | $3.30B | $535.15B |
Dividend Yield | — | 1.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
Oracle Corporation (ORCL) is trading at $135.56, down 5.58% amid broader market volatility despite strong Q1 2026 earnings that beat expectations with EPS of $2.11 versus $1.96. The stock faces technical bearish signals with support at $133 and resistance at $141, while fundamentals show robust revenue growth to $57.4B in 2025 and net income margin expansion to 26.36%. Recent AI-driven infrastructure investments and layoffs highlight strategic shifts to capitalize on cloud demand.
Oracle's outlook remains positive with analyst consensus price target of $236.52 implying 74% upside, supported by 65% buy ratings. Key opportunities include AI cloud revenue growth accelerating 120% in Q1 2026, though risks persist from high debt levels ($85.3B long-term) and sensitivity to Fed policy given the stock's 1.9 beta. Investors should weigh strong profitability against execution risks in aggressive data center expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →
